Cargando…

Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma

BACKGROUND: Current guidelines recommend neoadjuvant chemotherapy in patients with locoregional gastric adenocarcinoma. Patients diagnosed with early stage gastric adenocarcinoma are usually managed with upfront surgical intervention. However, pathologic staging in a subset of these clinically stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Margalit, Ofer, Shacham‐Shmueli, Einat, Yang, Yu‐Xiao, Lawerence, Yaacov R., Levy, Idan, Reiss, Kim A., Golan, Talia, Halpern, Naama, Aderka, Dan, Giantonio, Bruce, Mamtani, Ronac, Boursi, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794188/
https://www.ncbi.nlm.nih.gov/pubmed/32969129
http://dx.doi.org/10.1002/onco.13542
_version_ 1783634154012803072
author Margalit, Ofer
Shacham‐Shmueli, Einat
Yang, Yu‐Xiao
Lawerence, Yaacov R.
Levy, Idan
Reiss, Kim A.
Golan, Talia
Halpern, Naama
Aderka, Dan
Giantonio, Bruce
Mamtani, Ronac
Boursi, Ben
author_facet Margalit, Ofer
Shacham‐Shmueli, Einat
Yang, Yu‐Xiao
Lawerence, Yaacov R.
Levy, Idan
Reiss, Kim A.
Golan, Talia
Halpern, Naama
Aderka, Dan
Giantonio, Bruce
Mamtani, Ronac
Boursi, Ben
author_sort Margalit, Ofer
collection PubMed
description BACKGROUND: Current guidelines recommend neoadjuvant chemotherapy in patients with locoregional gastric adenocarcinoma. Patients diagnosed with early stage gastric adenocarcinoma are usually managed with upfront surgical intervention. However, pathologic staging in a subset of these clinically staged patients identifies more advanced locoregional disease requiring adjuvant treatment. Therefore, identifying these patients prior to surgical intervention is critical to ensure employment of the appropriate treatment paradigm. The aim of the current study was to define patient characteristics associated with clinical understaging in early gastric cancer. METHODS: Using the National Cancer Database (2004–2014) we identified 3,892 individuals with clinical T1N0 gastric adenocarcinoma who underwent upfront definitive surgery, had negative surgical margins, and did not receive preoperative chemotherapy or radiotherapy. Patient characteristics were compared between those with pathologic stage T1N0 disease and those who were upstaged upon surgery. RESULTS: Twenty‐seven percent of clinical T1N0 gastric adenocarcinomas had a change in stage because of pathologically defined ≥T2 disease or positive lymph nodes. Individuals who were upstaged had a higher tumor grade compared with those with pathologic stage T1N0 disease. Specifically, 41.9% (530/1,264) of individuals with a poorly differentiated tumor were upstaged, compared with only 10.7% (70/656) with a well‐differentiated tumor. Approximately 75% of cases involved upstaging because of T misclassification. The highest percentage of upstaging was shown for tumors located at the fundus and body of the stomach. CONCLUSION: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy. IMPLICATIONS FOR PRACTICE: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy.
format Online
Article
Text
id pubmed-7794188
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-77941882021-01-15 Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma Margalit, Ofer Shacham‐Shmueli, Einat Yang, Yu‐Xiao Lawerence, Yaacov R. Levy, Idan Reiss, Kim A. Golan, Talia Halpern, Naama Aderka, Dan Giantonio, Bruce Mamtani, Ronac Boursi, Ben Oncologist Gastrointestinal Cancer BACKGROUND: Current guidelines recommend neoadjuvant chemotherapy in patients with locoregional gastric adenocarcinoma. Patients diagnosed with early stage gastric adenocarcinoma are usually managed with upfront surgical intervention. However, pathologic staging in a subset of these clinically staged patients identifies more advanced locoregional disease requiring adjuvant treatment. Therefore, identifying these patients prior to surgical intervention is critical to ensure employment of the appropriate treatment paradigm. The aim of the current study was to define patient characteristics associated with clinical understaging in early gastric cancer. METHODS: Using the National Cancer Database (2004–2014) we identified 3,892 individuals with clinical T1N0 gastric adenocarcinoma who underwent upfront definitive surgery, had negative surgical margins, and did not receive preoperative chemotherapy or radiotherapy. Patient characteristics were compared between those with pathologic stage T1N0 disease and those who were upstaged upon surgery. RESULTS: Twenty‐seven percent of clinical T1N0 gastric adenocarcinomas had a change in stage because of pathologically defined ≥T2 disease or positive lymph nodes. Individuals who were upstaged had a higher tumor grade compared with those with pathologic stage T1N0 disease. Specifically, 41.9% (530/1,264) of individuals with a poorly differentiated tumor were upstaged, compared with only 10.7% (70/656) with a well‐differentiated tumor. Approximately 75% of cases involved upstaging because of T misclassification. The highest percentage of upstaging was shown for tumors located at the fundus and body of the stomach. CONCLUSION: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy. IMPLICATIONS FOR PRACTICE: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy. John Wiley & Sons, Inc. 2020-10-20 2021-01 /pmc/articles/PMC7794188/ /pubmed/32969129 http://dx.doi.org/10.1002/onco.13542 Text en © 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Gastrointestinal Cancer
Margalit, Ofer
Shacham‐Shmueli, Einat
Yang, Yu‐Xiao
Lawerence, Yaacov R.
Levy, Idan
Reiss, Kim A.
Golan, Talia
Halpern, Naama
Aderka, Dan
Giantonio, Bruce
Mamtani, Ronac
Boursi, Ben
Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
title Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
title_full Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
title_fullStr Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
title_full_unstemmed Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
title_short Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
title_sort prognostic implications of tumor differentiation in clinical t1n0 gastric adenocarcinoma
topic Gastrointestinal Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794188/
https://www.ncbi.nlm.nih.gov/pubmed/32969129
http://dx.doi.org/10.1002/onco.13542
work_keys_str_mv AT margalitofer prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT shachamshmuelieinat prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT yangyuxiao prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT lawerenceyaacovr prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT levyidan prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT reisskima prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT golantalia prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT halpernnaama prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT aderkadan prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT giantoniobruce prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT mamtanironac prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma
AT boursiben prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma